Physician

Farah Nasraty

According to 2025 Medicare claims, Farah Nasraty (NPI: 1104244813) practices hematology/oncology in the San Diego-Chula Vista-Carlsbad, CA market, with the plurality of this provider's patient population coming from San Diego, CA. This provider's primary affiliated billing organization is SCRIPPS HEALTH (NPI: 1275899072; TIN: 232380812) and primary practice location at 92128-3491. Nasraty is affiliated with the Scripps Accountable Care Organization, LLC (ACO ID: A3521), participating under the MSSP model.

Nasraty's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,025 traditional Medicare patients, billed 237,711 HCPCS/CPT codes, and received $3,698,609 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,304 prescription claims across 297 beneficiaries totaling $1,411,743 in drug costs, led by Lynparza (Olaparib). DME data shows 66 claims. Open Payments data shows 57 records totaling $1,330. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have risen steadily, from $10,759 to $1,411,743. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	380	42,150	$830,446
2022	699	176,491	$2,525,582
2023	761	162,106	$2,472,731
2024	1,025	237,711	$3,698,609

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	30	248	$10,759
2016	33	239	$33,781
2017	19	126	$12,596
2018	N/R	18	$407
2019	35	119	$107,362
2020	29	139	$186,360
2021	205	534	$446,221
2022	341	1,414	$1,152,882
2023	326	1,387	$1,319,289
2024	297	1,304	$1,411,743

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	88	$2,793
2023	12	65	$7,469
2024	N/R	66	$2,770

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	188	647	$118
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	455	853	$98
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	206	353	$54
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	167	225	$13
96372	Injection of drug or substance under skin or into muscle	128	299	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lynparza	Olaparib	36	1,080	$431,382
Ibrance	Palbociclib	23	644	$356,825
Verzenio	Abemaciclib	16	448	$227,841
Eliquis	Apixaban	19	855	$16,654
Exemestane	Exemestane	85	5,850	$16,498

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	13	$1,380
J8521	Capecitabine, oral, 500 mg	N	N/R	22	$780
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	15	$309
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	57	$1,330	Alexion Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Farah Nasraty?

Tedicare shows public-source Medicare data for Farah Nasraty (NPI 1104244813), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Farah Nasraty have ACO affiliation data?

Farah Nasraty is shown with ACO affiliation data for Scripps Accountable Care Organization, LLC (MSSP, ACO ID A3521).

What billing organization is linked to Farah Nasraty?

Farah Nasraty is linked to SCRIPPS HEALTH (billing NPI 1275899072) in the available physician profile data.

Does Farah Nasraty have Open Payments data?

Farah Nasraty has 57 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.